CEO: | Phil L'Huillier |
CFO: | Sath Nirmalananthan |
Chief Scientific Officer: | Lindy Durrant |
Deputy Chairman: | Susan Clement Davies |
Non-Executive Chairman: | Jean-Michel Cosséry |
Non-Executive Dir: | Martin Diggle , Ursula Ney, Florian Reinaud |
Address: | Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, United Kingdom , OX4 4GD |
Website: | http://www.scancell.co.uk/ |
Sector: | Pharma and Biotech(LSE) |
Index: | FTSE AIM All-Share |
ISIN: | GB00B63D3314 |
Currency | UK Pounds |
Share Price | 14.50p |
Change Today | -0.50p |
% Change | -3.33 % |
52 Week High | 19.50 |
52 Week Low | 8.92 |
Volume | 601,540 |
Shares Issued | 927.98m |
Market Cap | £134.56m |
Beta | 0.49 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:29 | 100 @ 14.11p |
16:24 | 46 @ 14.00p |
16:23 | 50,285 @ 14.31p |
15:24 | 30,000 @ 14.50p |
15:23 | 50,000 @ 14.50p |
CFO | Sath Nirmalananthan |
CEO | Phil L'Huillier |
You are here: research